NextFin news, ISLE OF PALMS, S.C. — On Wednesday, October 1, 2025, the Trump administration implemented a new 100% import tariff on certain imported pharmaceutical drugs, a move designed to encourage pharmaceutical companies to establish or expand production facilities within the United States.
President Donald Trump announced the tariff as part of a broader strategy to promote domestic pharmaceutical manufacturing and reduce reliance on foreign drug imports. The tariff applies to imported branded medications but excludes generic drugs and imports from the European Union, which already has a 10% tax agreement with the U.S.
Mark Witte, an economics professor at the College of Charleston, explained that the tariff targets companies without a substantial U.S. footprint, defined by the administration as having a facility either under construction or operational in the country. This policy aims to incentivize companies, particularly those from China and India, to establish manufacturing bases in the U.S. to gain patent protections and market access.
Joe Gandy, manager of Isle of Palms Delta Pharmacy, noted that the majority of prescriptions filled in South Carolina are generic drugs, which are exempt from the tariff. He indicated that most customers would likely not see immediate price increases on their medications due to this exemption.
Gandy also highlighted that pharmaceutical companies affected by the tariff might respond by creating domestic production footprints, which could help address supply chain issues experienced during the COVID-19 pandemic. He added that pharmacy benefit managers, who act as intermediaries in drug pricing, will decide whether to absorb the tariff costs or pass them on to consumers.
The U.S. Food and Drug Administration reports that approximately nine out of ten prescriptions filled in the country are for generic drugs, underscoring the limited direct impact of the tariff on most consumers.
This tariff policy coincides with the administration’s recent deal with Pfizer to lower drug prices and the planned launch of a government website to sell branded medications at negotiated prices, aiming to balance trade protections with consumer affordability.
The tariff’s implementation comes amid ongoing debates about drug pricing, supply chain resilience, and the role of domestic manufacturing in national economic strategy.
Explore more exclusive insights at nextfin.ai.
